DK2944323T3 - Midler til behandling af tumorer, anvendelse deraf og fremgangsmåde dertil - Google Patents

Midler til behandling af tumorer, anvendelse deraf og fremgangsmåde dertil Download PDF

Info

Publication number
DK2944323T3
DK2944323T3 DK13870762.5T DK13870762T DK2944323T3 DK 2944323 T3 DK2944323 T3 DK 2944323T3 DK 13870762 T DK13870762 T DK 13870762T DK 2944323 T3 DK2944323 T3 DK 2944323T3
Authority
DK
Denmark
Prior art keywords
cancer
cells
tumor
antibody
radiation
Prior art date
Application number
DK13870762.5T
Other languages
English (en)
Inventor
Yangxin Fu
Original Assignee
Dingfu Biotarget Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51166501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2944323(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dingfu Biotarget Co Ltd filed Critical Dingfu Biotarget Co Ltd
Application granted granted Critical
Publication of DK2944323T3 publication Critical patent/DK2944323T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Oncology (AREA)

Claims (11)

1. B7-H1-blokerende antistof til anvendelse i en fremgangsmåde til behandling af cancer i kombination med en strålebehandling, hvor det B7-H1-blokerende antistof indgives efter strålebehandlingen, og hvor det B7-H1-blokerende antistof er et anti-B7-H1 -antistof.
2. B7-H1-blokerende antistof til anvendelse ifølge krav 1, som er et monoklo-nalt antistof mod B7-H1.
3. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor strålebehandlingen er røntgenbestråling.
4. B7-H1-blokerende antistof til anvendelse ifølge krav 3, hvor strålebehandlingen er en enkelt eller flerfoldig røntgenbestråling.
5. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 3-4, hvor strålebehandlingen er 1,2, 3, 4, 5, 6 eller flere røntgen bestrålinger.
6. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 3-5, hvor den anvendte røntgendosis i hver bestråling er 5-20 Gy.
7. B7-H1-blokerende antistof til anvendelse ifølge krav 6, hvor den anvendte røntgendosis i hver bestråling er 5-8, 5-12 eller 5-15 Gy.
8. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 1 -7, hvor canceren er udvalgt fra gruppen bestående af brystcancer, ovariecancer, blærecancer, lungecancer, prostatacancer, pancreascancer, colon-cancer og melanom.
9. B7-H1-blokerende antistof til anvendelse ifølge krav 8, hvor canceren er brystcancer eller prostatacancer.
10. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor fremgangsmåden endvidere omfatter indgivelse af et kemoterapeutisk middel.
11. B7-H1-blokerende antistof til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor det B7-H1-blokerende antistof indgives inden for 9 dage efter strålebehandlingen.
DK13870762.5T 2013-01-11 2013-01-11 Midler til behandling af tumorer, anvendelse deraf og fremgangsmåde dertil DK2944323T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/070342 WO2014107873A1 (zh) 2013-01-11 2013-01-11 用于肿瘤治疗的试剂、其用途及方法

Publications (1)

Publication Number Publication Date
DK2944323T3 true DK2944323T3 (da) 2019-04-15

Family

ID=51166501

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13870762.5T DK2944323T3 (da) 2013-01-11 2013-01-11 Midler til behandling af tumorer, anvendelse deraf og fremgangsmåde dertil

Country Status (7)

Country Link
US (1) US20150344577A1 (da)
EP (1) EP2944323B1 (da)
CA (1) CA2896797A1 (da)
DK (1) DK2944323T3 (da)
ES (1) ES2721168T3 (da)
HR (1) HRP20190628T1 (da)
WO (1) WO2014107873A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP2017507900A (ja) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
CN110731961A (zh) 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
US12448448B2 (en) 2018-06-20 2025-10-21 Incyte Corporation Anti-PD-1 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) * 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013078392A1 (en) * 2011-11-21 2013-05-30 The University Of Chicago Methods and compositions involving induced senescent cells for cancer treatment
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도

Also Published As

Publication number Publication date
CA2896797A1 (en) 2014-07-17
US20150344577A1 (en) 2015-12-03
EP2944323B1 (en) 2019-03-27
EP2944323A1 (en) 2015-11-18
ES2721168T3 (es) 2019-07-29
EP2944323A4 (en) 2016-07-27
HRP20190628T1 (hr) 2019-06-14
WO2014107873A1 (zh) 2014-07-17

Similar Documents

Publication Publication Date Title
DK2944323T3 (da) Midler til behandling af tumorer, anvendelse deraf og fremgangsmåde dertil
ES2943640T3 (es) Combinación de anticuerpos anti-PD-1 y radiación para tratar el cáncer
KR102628557B1 (ko) 폐암의 치료를 위한 항-pd-1 항체
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
JP2020128432A (ja) がんの処置のための併用治療
CN116437954A (zh) 用于治疗癌症的组合
WO2014142220A1 (ja) 抗腫瘍剤
US20200377596A1 (en) Dosing of bispecific t cell engager
Sun et al. Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges
CN102935228B (zh) 用于肿瘤治疗的试剂、其用途及方法
AU2019266231B2 (en) Selection of patients for combination therapy
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
Persson et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies
Mazzola et al. The Abscopal Effect Combining Low/High Doses Radiation and Immunotherapy
WO2023210042A1 (ja) Ｉｌ－３４を発現する腫瘍を治療および／または予防するための医薬
van Zandwijk et al. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural
TW201718851A (zh) 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
Azhar et al. Perception on Immune Checkpoint Inhibitor Vanquishing Standard Treatment Paradigm for Triple-negative Breast Cancer
HK40002353A (en) Methods of treating skin cancer by administering a pd-1 inhibitor
HK40002353B (en) Methods of treating skin cancer by administering a pd-1 inhibitor
JP2016104704A (ja) 抗腫瘍剤
HK1259027A1 (zh) 具有抗趋除特性的修饰的t细胞及其用途